Skip over global navigation links
U.S. Department of Health and Human Services

BARDA supports new broad-spectrum antibiotic against glanders, melioidosis

Date: June 25, 2013 

Company: Basilea Pharmaceutica International Ltd., Basel, Switzerland

Contract amount: BARDA will provide $16.8 million in the first phase of the contract. The contract can be extended up to a total of six years with BARDA contributing up to a total of $89 million

About the contract: This contract is a cost-sharing public-private partnership. The partnership supports Basilea in conducting studies to evaluate the safety and efficacy of the antibiotic BAL30072 to treat Gram-negative infections including melioidosis, glanders, hospital-acquired pneumonia, and complicated urinary tract infections. Results from these studies will support the eventual filing of a new drug application with the FDA. In addition to showing promise in treating melioidosis and glanders, early studies of BAL30072 have demonstrated the drug’s potential in treating a broad range of multidrug-resistant Gram-negative bacteria commonly found in hospitals.

Additional information: BARDA is seeking additional proposals for broad-spectrum antimicrobials that potentially could treat or prevent diseases caused by bacterial and viral threat agents, and clinically relevant emerging and drug resistant pathogens that through the Broad Agency Announcement BARDA CBRN BAA-12-100-SOL-00011 at www.fbo.gov.

Press Release: BARDA supports new broad-spectrum antibiotic

PHE Newsroom

Submit an Inquiry

 

Watch, Listen, Subscribe

 
Facebook Exit Icon Twitter Exit Icon YouTube Exit Icon
Email via GovDelivery Exit Icon LinkedIn Exit Icon

  • This page last reviewed: April 28, 2017